Likelihood of Approval and Phase Transition Success Rate Model – Dasatinib in Non-Small Cell Lung Cancer
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Dasatinib in Non-Small Cell Lung Cancer report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Dasatinib in Non-Small Cell Lung Cancer Drug Details:
Dasatinib (Sprycel) is an anti-neoplastic agent. It is formulated as tablets, film coated tablets, coated tablets and powder for suspension for oral administration. It is indicated for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib in adults and also for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy in adults. Sprycel is also indicated for the treatment of adults and pediatrics with newly diagnosed Philadelphia chromosome – positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, and also indicated for the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.Dasatinib is under development for the treatment of inflammation caused by Coronavirus disease 2019 (COVID-19), non-small cell lung cancer, breast cancer (adjuvant), chronic myelocytic leukemia (1L, 2L) and acute lymphocytic leukemia (2L). It is administered by oral route. The drug candidate was also under development for the treatment of estrogen/progesterone receptor-positive or Her2/Neu-positive breast cancer, pancreatic cancer, relapsed or refractory diffuse large B-cell lymphoma, scleroderma pulmonary interstitial fibrosis, relapsed multiple myeloma, agnogenic myeloid metaplasia – myelofibrosis, hypereosinophilic syndrome, acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, systemic mastocytosis, oligodendroglioma, peripheral T-cell lymphoma, refractory multiple myeloma, melanoma, intrahepatic cholangiocarcinoma, metastatic breast cancer, HER2 negative breast cancer, recurrent glioblastoma, gliosarcoma, pulmonary arterial hypertension and non-Hodgkin lymphoma including Mantle cell lymphoma, diffuse large B cell lymphoma, natural killer cell lymphoma, follicular lymphoma, marginal zone lymphoma, lymphoblastic lymphoma and HIV infection. It was under development for the treatment of triple-negative breast cancer.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Dasatinib LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports